

ASX Announcement

Investor webinar – Imugene & Kincell Bio strategic partnership

Sydney, Australia, 17 April 2024: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce it will hold an investor webinar on Thursday 18 April 2024 at 10am AEST to discuss the strategic partnership announced with Kincell Bio, LLC (see ASX announcement 16 April 2024).

Presenting as part of the webinar will be Imugene's Managing Director and CEO Leslie Chong, Chief Operating Officer Dr Bradley Glover and Kincell Bio's CEO Dr Bruce Thompson. It will be hosted by Imugene's U.S. Head of Investor Relations Heather Armstrong.

Shareholders, investors and other interested parties are encouraged to register for the webinar at the following link:

https://us02web.zoom.us/webinar/register/WN_WkUvgUJSQbGJwNey7WujMA

After registering, you will receive a confirmation email with details on how to join the webinar. A recording will be available at the same link shortly after the conclusion of the session.

Investors are encouraged to send questions prior to the webinar to matt@nwrcommunications.com.au

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com



Media Enquiries

Matt Wright

matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.